You can buy or sell ARPO and other stocks, options, ETFs, and crypto commission-free!
Aerpio Pharmaceuticals, Inc. Common Stock, also called Aerpio Pharmaceuticals, is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Read More Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 22
Aerpio Pharmaceuticals: Eye Spy An Opportunity
Other comforting facts. (A dozen more reasons why I think now is the time to invest). Existing partnership could generate 10x current market cap in milestones and royalties, not to mention a portion of sales proceeds. According to Aerpio Pharmaceuticals (NASDAQ:ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readou...
Expected Aug 13, Pre-Market